View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMedesis Pharma 과거 순이익 실적과거 기준 점검 0/6Medesis Pharma 의 수입은 연평균 -26%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 13.3%의 비율로 증가해 왔습니다.핵심 정보-25.99%순이익 성장률-20.05%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률13.26%자기자본이익률n/a순이익률-4,924.73%최근 순이익 업데이트30 Jun 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .공시 • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues FranceNew Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).공시 • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.매출 및 비용 세부 내역Medesis Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:76D 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 240-31031 Mar 240-41031 Dec 230-41030 Sep 230-31030 Jun 230-31031 Mar 230-31031 Dec 220-31030 Sep 220-31030 Jun 220-31031 Mar 220-31031 Dec 210-31030 Sep 210-21030 Jun 210-21031 Mar 210-11031 Dec 200-100양질의 수익: 76D 은(는) 현재 수익성이 없습니다.이익 마진 증가: 76D는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 76D은 수익성이 없으며 지난 5년 동안 손실이 연평균 26% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 76D의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 76D은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(39.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 76D의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/15 20:40종가2025/03/11 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medesis Pharma S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .
공시 • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues France
New Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
공시 • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.